“I do not take the market’s view as gospel truth, but I also do not assume it is foolish or stupid”
ASK Group’s Bharat Shah on why the market is his guidepost when it comes to deciphering tangible price and intangible value
N Mahalakshmi - October 17, 2020
Chronic profit
Eris Lifesciences promoter Himanshu Shah sells stock worth ₹968 million
Shailaja Mohapatra - October 08, 2020
Take a chill pill
Work from home can be stressful. Let PharmEasy make one chore easier for you
Shailaja Mohapatra - October 06, 2020
Why Aarti Industries’ low-cost manufacturing and relationship with MNCs will power its growth
Customers have begun to prefer long-term contracts because they want supply security, reveals managing director Rajendra Gogri
Krishna Gopalan - September 30, 2020
Welcome to the Mad Hatters Party a.k.a investors going overboard on 'quality' companies
The market has been behaving erratically but amid the insanity here are some sane observations
N Mahalakshmi - September 30, 2020
Building a future-ready, innovative healthcare industry
India’s scientific excellence provides us the opportunity to achieve self-reliance in pharmaceuticals, biopharma and holistic care
Kiran Mazumdar-Shaw - August 28, 2020
Astec LifeSciences MD Ashok Hiremath sells stock worth ₹165 million
The stock has rallied on the back of strong earnings growth and overall optimism for pharma sector
Shailaja Mohapatra - August 13, 2020
When Wind Met Sun
In 2015, Dilip Shanghvi raised eyebrows when he invested Rs.18 billion in Suzlon
Krishna Gopalan - July 18, 2020
Is there more upside in store for pharma stocks?
Over the past year, the Nifty Pharma Index has gained 23% while the Nifty has declined by 11%
June 30, 2020
Will Glenmark’s COVID-19 drug give it a new lease of life or just a short energy boost?
The pharma major has taken a different path from peers, in launching a new drug instead of inking a licensing deal
Shruti Venkatesh - July 04, 2020
